LAWRENCE, Mass., July 20, 2011 /PRNewswire via COMTEX/ —
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Alan S. Kliger, MD, Clinical Professor of Medicine, Yale University School of Medicine and Chief Medical Officer, Hospital of St. Raphael, New Haven, Connecticut, has joined its Scientific Advisory Board (SAB).
A leader in the field of nephrology, Dr. Kliger joins the NxStage advisory board with extensive experience in research, teaching and clinical practice. He is a past president of the Forum of ESRD Networks and the Past President and current board member of the Renal Physicians Association.
Dr. Kliger also serves as the chairman of the steering committee for the Frequent Hemodialysis Network (FHN) trial funded by the National Institute of Health (NIH) and the Centers for Medicare & Medicaid Services (CMS), a long-term study that has documented how increasing hemodialysis to six times a week from the current standard of three times each week improved cardiovascular health and patient quality-of-life.
Alan’s work on landmark NIH research in more frequent hemodialysis has yielded objective evidence in support of its compelling clinical advantages, said Jeffrey H. Burbank, President and Chief Executive Officer, NxStage Medical, Inc. As we continue to grow the number of patients using the System One for more frequent home hemodialysis, we believe clinical data supports much broader adoption of our therapy. Alan will be an important advisor to NxStage as we work to promote clinical data and broaden access beyond current levels.
The improved outcomes we saw in the FHN randomized controlled trial of daily dialysis should encourage patients and their physicians to consider daily hemodialysis as a serious option, said Dr. Kliger. I’m excited to be involved with the team at NxStage, which is pioneering daily home dialysis with the System One in the U.S. and internationally.
NxStage SAB members include Alan R. Hull, MD, FACP, SAB Chairman and President of Renal Management, Inc.; Allan Collins, MD, FACP, Professor of Medicine, University of Minnesota; Frederic Finkelstein, MD, Chief of Nephrology, Hospital of St. Raphael and Clinical Professor of Medicine, Yale University; Joel Glickman, MD, FACP, Clinical Associate Professor of Medicine, University of Pennsylvania School of Medicine; Bertrand L. Jaber, MD, FASN, Vice Chair for Clinical Affairs, Department of Medicine, Caritas St. Elizabeth‘s Medical Center; Michael A. Kraus, MD, Professor of Clinical Medicine and Clinical Coordinator, Division of Nephrology, Medical Director of Home and Acute Dialysis, Indiana University Medical School and Clarian Health Partners; Brent Miller, MD, Associate Professor of Medicine, Director, Dialysis Home Modalities, Washington University School of Medicine; Les Spry, MD, Clinical Professor of Medicine at the University of Nebraska and Creighton University, Medical Director of Dialysis Center of Lincoln, NE; Brigitte Schiller, MD, Chief Medical Officer, Satellite Healthcare and Adjunct Clinical Assistant Professor, Division of Nephrology, Stanford University; John Burkart, MD, Professor of Internal Medicine/Nephrology, Wake Forest University School of Medicine, Chief Medical Officer, Health Systems Management; and Roger N Greenwood MSc ACGI MD FRCP, Consultant Nephrologist, East and North Herts NHS Trust, Stevenage, UK.
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company’s website at www.nxstage.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. The forward-looking statements in this release include NxStage’s efforts or plans to promote and expand clinical data and broaden access to the therapy. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors that are discussed in NxStage’s quarterly report on Form 10-Q for the period ended March 31, 2011 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
SOURCE NxStage Medical, Inc.